ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

ACAD

Classifica tra le azioni #4560
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Prezzo delle azioni
$19.62
Capitalizzazione di mercato
$3.38B
Variazione (1 giorno)
2.59%
Variazione (1 anno)
-6.10%
Paese
US
Scambia ACADIA Pharmaceuticals Inc. (ACAD)

Categoria

Healthcare
Storico del rendimento da dividendi per ACADIA Pharmaceuticals Inc. (ACAD)
Il rendimento da dividendi (TTM) di ACADIA Pharmaceuticals Inc. (simbolo azionario: ACAD) al 2023-12-31 è: 0.00%
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per ACADIA Pharmaceuticals Inc. (ACAD) da 2000 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% 0.00%
2008 0.00% 0.00%
2007 0.00% 0.00%
2006 0.00% 0.00%
2005 0.00% 0.00%
2004 0.00% 0.00%
2003 0.00% 0.00%
2002 0.00% 0.00%
2001 0.00% 0.00%
2000 0.00% 0.00%
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.17%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL